Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses QURE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named QURE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Matthew Kapusta | $676,170 | $0 | $1,079,100 | $1,155,960 | $345,117 | $0 | $31,087 | $3,287,434 |
| Chief Executive Officer and Executive Director | ||||||||
| Christian Klemt | 539,220 | 0 | 795,700 | 851,760 | 197,755 | 0 | 22,975 | 2,407,410 |
| Chief Financial Officer | ||||||||
| Walid Abi-Saab | 583,798 | 0 | 414,200 | 446,160 | 258,250 | 0 | 103,230 | 1,805,638 |
| Chief Medical Officer | ||||||||
| Jeannette Potts | 495,012 | 0 | 381,500 | 405,600 | 178,344 | 0 | 39,471 | 1,499,927 |
| Chief Legal and Compliance Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Matthew Kapusta | $3,287,434 | $3,075,938 | $6,584,919 | +211,496 |
| Christian Klemt | 2,407,410 | 1,327,533 | 2,116,548 | +1,079,877 |
| Walid Abi-Saab | 1,805,638 | 1,499,857 | — | +305,781 |
| Jeannette Potts | 1,499,927 | 1,292,272 | 2,310,848 | +207,655 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Walid Abi-Saab | Chief Medical Officer | 2026-05-08 | D | 25,000 | $25 | $627,500 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-05-08 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-05-08 | D | 20,000 | 25 | 500,000 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-05-08 | A | 25,000 | 6 | 139,750 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-03 | A | 2,645 | 16 | 42,426 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-03 | D | 2,645 | 30 | 79,376 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-03 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 3,127 | 26 | 81,396 | Common | Form 4 ↗ |
| David Meek | Director | 2026-06-10 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Jeremy Springhorn | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Springhorn | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-10 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 2,645 | 26 | 68,955 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 1,780 | 26 | 46,369 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Springhorn | Director | 2026-06-10 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-06-10 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| David Meek | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Leonard Post | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | A | 2,645 | 16 | 42,426 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Leonard Post | Director | 2026-06-10 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| David Meek | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-10 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Leonard Post | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 2,726 | 27 | 73,766 | Common | Form 4 ↗ |
| Kylie O'Keefe | Chief Customer & Strat Officer | 2026-06-11 | D | 15,936 | 27 | 431,228 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-15 | A | 10,000 | 8 | 84,900 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-15 | D | 10,000 | 28 | 278,500 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-15 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeannette Potts | Chief Legal Officer | 2026-06-15 | D | 5,237 | 28 | 144,908 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 6,390 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | A | 62,581 | 19 | 1,213,446 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 56,929 | 43 | 2,472,426 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 11,585 | 49 | 563,610 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 37,015 | 50 | 1,850,750 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 4,656 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | A | 6,390 | 19 | 123,902 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 1,690 | 43 | 71,994 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 5,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-17 | A | 5,295 | 32 | 167,904 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-17 | D | 5,295 | 43 | 225,408 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 4,700 | 44 | 205,202 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | A | 5,295 | 32 | 167,904 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 62,581 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 32,581 | 45 | 1,466,797 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 6,023 | 44 | 263,205 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 23,977 | 43 | 1,021,660 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 33,334 | 45 | 1,500,363 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | A | 4,656 | 32 | 147,642 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 4,656 | 50 | 232,800 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 5,295 | 47 | 249,289 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-17 | D | 5,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | A | 4,128 | 32 | 130,899 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | D | 28,716 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | D | 6,696 | 50 | 334,800 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | D | 4,128 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | D | 28,716 | 50 | 1,436,374 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | A | 28,716 | 32 | 910,584 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-26 | D | 1,434 | 47 | 67,197 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-30 | A | 10,000 | 6 | 55,900 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | D | 17,060 | 46 | 792,096 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | D | 4,107 | 46 | 190,934 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | A | 17,060 | 20 | 344,271 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | A | 4,107 | 37 | 151,959 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-30 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-30 | D | 20,000 | 46 | 928,000 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | D | 17,060 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | D | 4,107 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-30 | D | 10,000 | 46 | 464,600 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | A | 21,082 | 19 | 408,780 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | D | 9,200 | 44 | 408,756 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | D | 7,600 | 46 | 348,764 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | D | 4,282 | 45 | 194,531 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | D | 21,082 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Walid Abi-Saab | RSU | 2025-03-03 | — | — | 38,000 | — | $414,200 |
| Matthew Kapusta | RSU | 2025-03-03 | — | — | 99,000 | — | 1,079,100 |
| Walid Abi-Saab | OPTION | 2025-03-03 | — | — | 66,000 | — | 446,160 |
| Jeannette Potts | OPTION | 2025-03-03 | — | — | 60,000 | — | 405,600 |
| Christian Klemt | OPTION | 2025-03-03 | — | — | 126,000 | — | 851,760 |
| Jeannette Potts | RSU | 2025-03-03 | — | — | 35,000 | — | 381,500 |
| Christian Klemt | RSU | 2025-03-03 | — | — | 73,000 | — | 795,700 |
| Matthew Kapusta | OPTION | 2025-03-03 | — | — | 171,000 | — | 1,155,960 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Walid Abi-Saab | $414,200 | $0 | $446,160 | 0.0% |
| Matthew Kapusta | 1,079,100 | 0 | 1,155,960 | 0.0% |
| Jeannette Potts | 381,500 | 0 | 405,600 | 0.0% |
| Christian Klemt | 795,700 | 0 | 851,760 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Kapusta | Option | 171,000 | 10.9 | — |
| Matthew Kapusta | Option | 13,486 | 16.04 | — |
| Jeannette Potts | Option | 48,096 | 5.59 | — |
| Matthew Kapusta | RSU | 99,000 | — | 2,369,070 |
| Walid Abi-Saab | RSU | 33,001 | — | 789,714 |
| Christian Klemt | Option | 48,096 | 5.59 | — |
| Matthew Kapusta | Option | 145,971 | 5.59 | — |
| Matthew Kapusta | RSU | 100,001 | — | 2,393,024 |
| Jeannette Potts | Option | 60,000 | 10.9 | — |
| Matthew Kapusta | Option | 80,158 | 20.06 | — |
| Walid Abi-Saab | RSU | 38,000 | — | 909,340 |
| Walid Abi-Saab | RSU | 22,402 | — | 536,080 |
| Christian Klemt | Option | 20,158 | 20.06 | — |
| Christian Klemt | RSU | 12,468 | — | 298,359 |
| Walid Abi-Saab | Option | 43,428 | 11.47 | — |
| Christian Klemt | RSU | 73,000 | — | 1,746,890 |
| Jeannette Potts | RSU | 35,000 | — | 837,550 |
| Jeannette Potts | RSU | 33,001 | — | 789,714 |
| Christian Klemt | RSU | 33,001 | — | 789,714 |
| Walid Abi-Saab | Option | 48,096 | 5.59 | — |
| Christian Klemt | Option | 4,707 | 16.04 | — |
| Walid Abi-Saab | PSU | 25,000 | — | 598,250 |
| Jeannette Potts | RSU | 15,702 | — | 375,749 |
| Matthew Kapusta | RSU | 40,502 | — | 969,213 |
| Christian Klemt | Option | 126,000 | 10.9 | — |
our compensation program for all of our executive officers, including our NEOs, is designed to attract, retain, and incentivize the best possible talent
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | WTW (Willis Towers Watson) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 37,422,626 | 414,084 | 72,709 | 98.91% | Passed |
| 2025 | 2025-06-11 | 32,363,219 | 1,599,559 | 119,528 | 95.29% | Passed |
| 2024 | 2024-06-18 | 20,150,415 | 5,870,009 | 40,148 | 77.44% | Passed |
| 2022 | 2022-06-14 | 30,883,737 | 939,642 | 13,034 | 97.05% | Passed |
| 2019 | 2019-06-19 | 27,100,012 | 17,640 | 3,361 | 99.92% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-10 | 98.91%a |
| 2025 | 2025-06-11 | 95.29%b |
| 2024 | 2024-06-18 | 77.44%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 19 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $170,377 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David MeekIndependent · Board Chair · Compensation · Nominating/Governance · Commercial | $97,541 | $129,273 | $137,857 | — | $0 | $364,671 |
| Jeremy SpringhornIndependent · Audit · Nominating/Governance (Chair) · Research & Development · Commercial | 77,541 | 129,273 | 137,857 | — | 0 | 344,671 |
| Jack KayeIndependent · Audit (Chair) · Compensation | 72,500 | 129,273 | 137,857 | — | 0 | 339,630 |
| Rachelle JacquesIndependent · Audit · Nominating/Governance · Commercial (Chair) | 70,082 | 129,273 | 137,857 | — | 0 | 337,212 |
| Madhavan BalachandranIndependent · Compensation (Chair) · Commercial | 65,041 | 129,273 | 137,857 | — | 0 | 332,171 |
| Leonard PostIndependent · Research & Development (Chair) | 60,000 | 129,273 | 137,857 | — | 0 | 327,130 |
| Robert GutIndependent · Research & Development | 52,500 | 129,273 | 137,857 | — | 0 | 319,630 |
| Matthew KapustaEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | All Executive Officers have satisfied, or are on track to satisfy within the five-year grace period, the Board's stock ownership guidelines. |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $495,205 |
| Equity awards (grant-date value) | $904,911 |
| All other compensation | $0 |
| Total cost of the board | $1,400,116 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies uniQure names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including uniQure.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Revance Therapeutics | 2023 | Mark Foley | 720,000 | 8,810,731 | 0 | 522,720 | 10,068,915 |
| 3 | Travere Therapeutics | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 4 | Verve Therapeutics | 2024 | Sekar Kathiresan | 639,231 | 1,683,000 | 4,727,372 | 378,972 | 7,442,663 |
| 5 | Solid Biosciences | 2025 | Alexander Cumbo | 650,988 | 2,318,275 | 1,792,397 | 0 | 5,223,442 |
| 6 | uniQure | 2025 | Matthew Kapusta | 676,170 | 1,079,100 | 1,155,960 | 345,117 | 3,287,434 |
| 7 | C4 Therapeutics | 2025 | Andrew Hirsch | 694,925 | 710,730 | 848,007 | 573,313 | 2,940,975 |
| 8 | Voyager Therapeutics | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 9 | Foghorn Therapeutics | 2025 | Adrian Gottschalk | 638,000 | 0 | 1,334,037 | 385,990 | 2,361,027 |
| 10 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| — | Wave Life Sciences | — | — | — | — | — | — | not in coverage universe |
| — | Sangamo Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Stoke Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| uniQure | not disclosed | Options 50 · RSU 50 | No | WTW (Willis Towers Watson) |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| C4 Therapeutics | 120% | not disclosed | not disclosed | Pearl Meyer |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Foghorn Therapeutics | not disclosed | Options 100 | not disclosed | Pay Governance, LLC |
| Revance Therapeutics | 96.8% | PSU 100 | No | FW Cook |
| Sangamo Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Solid Biosciences | 100% | not disclosed | No | Radford (AON Hewitt) |
| Stoke Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Travere Therapeutics | 150% | not disclosed | No | Aon |
| Verve Therapeutics | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
| Voyager Therapeutics | 97.5% | not disclosed | No | Alpine Rewards, LLC |
| Wave Life Sciences | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Matthew Kapusta | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Summary Compensation Table” · page 71. As printed: 3,287,434. Filing ↗machine: t139 · r2 · c16 · span 1000603–1000612 |
| 2 | Section 01, Christian Klemt | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “SUMMARY COMPENSATION TABLE” · page 71. As printed: 2,407,410. Filing ↗machine: r5 · c16 · span 1013980–1013989 |
| 3 | Section 01, Walid Abi-Saab | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “SUMMARY COMPENSATION TABLE” · page 71. As printed: 1,805,638. Filing ↗machine: r8 · c16 · span 1027035–1027044 |
| 4 | Section 01, Jeannette Potts | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “SUMMARY COMPENSATION TABLE” · page 71. As printed: 1,499,927. Filing ↗machine: t139 · r10 · c16 · span 1035842–1035851 |
| 5 | Section 03, Walid Abi-Saab RSU | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL 2025” · grants of plan-based awards table. Filing ↗machine: t147 · r31 · c14 · span 1237107–1237113 |
| 6 | Section 03, Matthew Kapusta RSU | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL 2025” · grants of plan-based awards table. Filing ↗machine: t147 · r13 · c14 · span 1139175–1139181 |
| 7 | Section 03, Walid Abi-Saab OPTION | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t139 · r8 · c8 · span 1024865–1024872 |
| 8 | Section 03, Jeannette Potts OPTION | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t139 · r10 · c8 · span 1033675–1033682 |
| 9 | Section 03, Christian Klemt OPTION | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t139 · r5 · c8 · span 1011811–1011818 |
| 10 | Section 03, Jeannette Potts RSU | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL 2025” · grants of plan-based awards table. Filing ↗machine: t147 · r38 · c14 · span 1275594–1275600 |
| 11 | Section 03, Christian Klemt RSU | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL 2025” · grants of plan-based awards table. Filing ↗machine: t147 · r25 · c14 · span 1204323–1204329 |
| 12 | Section 03, Matthew Kapusta OPTION | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t139 · r2 · c8 · span 998586–998595 |
| 13 | Section 07, pay ratio | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “CEO Pay Ratio”. As printed: 19 : 1. Filing ↗machine: t124 · r2 · c3 · span 924639–924646 |
| 14 | Section 08, David Meek | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Director Compensation”. As printed: 364,671. Filing ↗machine: t201 · r6 · c8 · span 1783201–1783208 |
| 15 | Section 08, Jeremy Springhorn | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Director Compensation”. As printed: 344,671. Filing ↗machine: t201 · r8 · c8 · span 1788001–1788008 |
| 16 | Section 08, Jack Kaye | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Director Compensation”. As printed: 339,630. Filing ↗machine: t201 · r5 · c8 · span 1780720–1780727 |
| 17 | Section 08, Rachelle Jacques | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Director Compensation”. As printed: 337,212. Filing ↗machine: t201 · r4 · c8 · span 1778411–1778418 |
| 18 | Section 08, Madhavan Balachandran | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Director Compensation”. As printed: 332,171. Filing ↗machine: t201 · r2 · c8 · span 1773614–1773621 |
| 19 | Section 08, Leonard Post | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Director Compensation”. As printed: 327,130. Filing ↗machine: t201 · r7 · c8 · span 1785513–1785520 |
| 20 | Section 08, Robert Gut | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Director Compensation”. As printed: 319,630. Filing ↗machine: t201 · r3 · c8 · span 1775924–1775931 |
| 21 | Section 08, Matthew Kapusta | DEF 14A | 2026-04-27 | 0001104659-26-048969 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 02, Walid Abi-Saab 2026-05-08 | Form 4 | 2026-05-12 | 0000904454-26-000260 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Walid Abi-Saab 2026-05-08 | Form 4 | 2026-05-12 | 0000904454-26-000260 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Walid Abi-Saab 2026-05-08 | Form 4 | 2026-05-12 | 0000904454-26-000260 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Walid Abi-Saab 2026-05-08 | Form 4 | 2026-05-12 | 0000904454-26-000260 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Jack Kaye 2026-06-03 | Form 4 | 2026-06-05 | 0000904454-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Jack Kaye 2026-06-03 | Form 4 | 2026-06-05 | 0000904454-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Jack Kaye 2026-06-03 | Form 4 | 2026-06-05 | 0000904454-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Robert Gut 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, David Meek 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000352 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Jeremy Springhorn 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000346 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Jeremy Springhorn 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000346 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Madhavan Balachandran 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000337 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Madhavan Balachandran 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000337 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Rachelle Jacques 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000339 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Robert Gut 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Robert Gut 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Robert Gut 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Robert Gut 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Jeremy Springhorn 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000346 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Rachelle Jacques 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000339 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Robert Gut 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, David Meek 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000352 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Leonard Post 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000344 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Robert Gut 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Jack Kaye 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000342 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Madhavan Balachandran 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000337 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Leonard Post 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000344 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, David Meek 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000352 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Rachelle Jacques 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000339 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Jack Kaye 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000342 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Jack Kaye 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000342 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Leonard Post 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000344 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Robert Gut 2026-06-10 | Form 4 | 2026-06-12 | 0000904454-26-000350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Kylie O'Keefe 2026-06-11 | Form 4 | 2026-06-12 | 0000904454-26-000348 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Madhavan Balachandran 2026-06-15 | Form 4 | 2026-06-17 | 0000904454-26-000366 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Madhavan Balachandran 2026-06-15 | Form 4 | 2026-06-17 | 0000904454-26-000366 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Madhavan Balachandran 2026-06-15 | Form 4 | 2026-06-17 | 0000904454-26-000366 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Jeannette Potts 2026-06-15 | Form 4 | 2026-06-17 | 0000904454-26-000364 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Madhavan Balachandran 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000370 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Madhavan Balachandran 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000370 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Madhavan Balachandran 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000370 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Madhavan Balachandran 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000370 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Jack Kaye 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000368 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Jack Kaye 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000368 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Madhavan Balachandran 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000370 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Madhavan Balachandran 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000370 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Matthew Kapusta 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000372 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Madhavan Balachandran 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000370 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jack Kaye 2026-06-17 | Form 4 | 2026-06-22 | 0000904454-26-000368 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Matthew Kapusta 2026-06-24 | Form 4 | 2026-06-26 | 0000904454-26-000375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Matthew Kapusta 2026-06-24 | Form 4 | 2026-06-26 | 0000904454-26-000375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Matthew Kapusta 2026-06-24 | Form 4 | 2026-06-26 | 0000904454-26-000375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Matthew Kapusta 2026-06-24 | Form 4 | 2026-06-26 | 0000904454-26-000375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Matthew Kapusta 2026-06-24 | Form 4 | 2026-06-26 | 0000904454-26-000375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Matthew Kapusta 2026-06-24 | Form 4 | 2026-06-26 | 0000904454-26-000375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Walid Abi-Saab 2026-06-26 | Form 4 | 2026-06-30 | 0000904454-26-000387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Walid Abi-Saab 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Jack Kaye 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Jack Kaye 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Jack Kaye 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Jack Kaye 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Walid Abi-Saab 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Walid Abi-Saab 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Jack Kaye 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Jack Kaye 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Walid Abi-Saab 2026-06-30 | Form 4 | 2026-07-02 | 0000904454-26-000394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Matthew Kapusta 2026-07-02 | Form 4 | 2026-07-07 | 0000904454-26-000397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Matthew Kapusta 2026-07-02 | Form 4 | 2026-07-07 | 0000904454-26-000397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Matthew Kapusta 2026-07-02 | Form 4 | 2026-07-07 | 0000904454-26-000397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Matthew Kapusta 2026-07-02 | Form 4 | 2026-07-07 | 0000904454-26-000397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Matthew Kapusta 2026-07-02 | Form 4 | 2026-07-07 | 0000904454-26-000397 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 06, 2026 vote | Form 8-K | 2026-06-15 | 0001104659-26-074067 | Item 5.07 · say-on-pay result. As reported: 98.91% (votes for as printed: 37,422,626). Filing ↗ |
| 105 | Section 06, 2025 vote | Form 8-K | 2025-06-13 | 0001558370-25-008627 | Item 5.07 · say-on-pay result. As reported: 95.29% (votes for as printed: 32,363,219). Filing ↗ |
| 106 | Section 06, 2024 vote | Form 8-K | 2024-06-20 | 0001558370-24-009305 | Item 5.07 · say-on-pay result. As reported: 77.44% (votes for as printed: 20,150,415). Filing ↗ |
| 107 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 108 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 109 | Section 09b board cost (computed) | Computed | — | computed | Cash 495,205 + equity 904,911 + all other 0 = 1,400,116, summed across the director compensation table rows.machine: formula: Σ = 1,400,116 |
| 110 | Cogent Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 111 | Revance Therapeutics, Section 10b CEO total | DEF 14A | 2024-03-21 | 0001479290-24-000071 | CEO total compensation as printed in Revance Therapeutics's own proxy. As printed: 10,068,915. Filing ↗machine: span 884809–884819 |
| 112 | Travere Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 113 | Verve Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-25 | 0000950170-25-058325 | CEO total compensation as printed in Verve Therapeutics's own proxy. As printed: 7,442,663. Filing ↗machine: r2 · c20 · span 327433–327442 |
| 114 | Solid Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173642 | CEO total compensation as printed in Solid Biosciences's own proxy. As printed: 5,223,442. Filing ↗machine: r2 · c25 · span 472915–472924 |
| 115 | uniQure (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001104659-26-048969 | CEO total compensation as printed in uniQure's own proxy. As printed: 3,287,434. Filing ↗machine: t139 · r2 · c16 · span 1000603–1000612 |
| 116 | C4 Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028104 | CEO total compensation as printed in C4 Therapeutics's own proxy. As printed: 2,940,975. Filing ↗machine: span 511808–511817 |
| 117 | Voyager Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050297 | CEO total compensation as printed in Voyager Therapeutics's own proxy. As printed: 2,508,370. Filing ↗machine: t9 · r1 · c47 · span 370852–370861 |
| 118 | Foghorn Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-193928 | CEO total compensation as printed in Foghorn Therapeutics's own proxy. As printed: 2,361,027. Filing ↗machine: r2 · c34 · span 245360–245369 |
| 119 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 120 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include uniQure. Filing ↗ |
| 121 | Section 10a, Revance Therapeutics reciprocity | DEF 14A | — | 0001479290-24-000071 | Revance Therapeutics's most recent proxy was read; its disclosed peer group does not include uniQure. Filing ↗ |
| 122 | Section 10a, Travere Therapeutics reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics's most recent proxy was read; its disclosed peer group does not include uniQure. Filing ↗ |
| 123 | Section 10a, Cogent Biosciences reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences's most recent proxy was read; its disclosed peer group does not include uniQure. Filing ↗ |
| 124 | Section 10a, C4 Therapeutics reciprocity | DEF 14A | — | 0001628280-26-028104 | C4 Therapeutics's most recent proxy was read; its disclosed peer group does not include uniQure. Filing ↗ |
| 125 | Section 10a, Voyager Therapeutics reciprocity | DEF 14A | — | 0001104659-26-050297 | Voyager Therapeutics's most recent proxy was read; its disclosed peer group does not include uniQure. Filing ↗ |